AU9763098A - Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds - Google Patents

Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Info

Publication number
AU9763098A
AU9763098A AU97630/98A AU9763098A AU9763098A AU 9763098 A AU9763098 A AU 9763098A AU 97630/98 A AU97630/98 A AU 97630/98A AU 9763098 A AU9763098 A AU 9763098A AU 9763098 A AU9763098 A AU 9763098A
Authority
AU
Australia
Prior art keywords
apoptosis
treatment
disorders associated
glyoxylamide compounds
heterocyclic glyoxylamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU97630/98A
Inventor
Nobuo Takasu
Tatsurou Yagami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU9763098A publication Critical patent/AU9763098A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU97630/98A 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds Abandoned AU9763098A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
WOJP9704104 1997-11-12
PCT/JP1997/004104 WO1999024033A1 (en) 1997-11-12 1997-11-12 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
PCT/JP1998/005042 WO1999024026A2 (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Publications (1)

Publication Number Publication Date
AU9763098A true AU9763098A (en) 1999-05-31

Family

ID=14181471

Family Applications (1)

Application Number Title Priority Date Filing Date
AU97630/98A Abandoned AU9763098A (en) 1997-11-12 1998-11-10 Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds

Country Status (5)

Country Link
EP (1) EP1037630A2 (en)
JP (1) JP2003522720A (en)
AU (1) AU9763098A (en)
CA (1) CA2308269A1 (en)
WO (2) WO1999024033A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115210280A (en) * 2020-03-05 2022-10-18 波音公司 Schiff base oligomer

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2341897A1 (en) * 1998-08-28 2000-03-09 Uropath Pty. Ltd. Method of diagnosis of prostate cancer
AU4834200A (en) * 1999-05-10 2000-11-21 Protarga, Inc. Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
WO2001014378A1 (en) * 1999-08-23 2001-03-01 Shionogi & Co., Ltd. PYRROLOTRIAZINE DERIVATIVES HAVING sPLA2-INHIBITORY ACTIVITIES
DE19962300A1 (en) * 1999-12-23 2001-06-28 Asta Medica Ag New N-benzylindolyl glyoxylic acid derivatives are useful as antitumor agents
AU2001267824A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cancer
US6867300B2 (en) 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
PL366376A1 (en) * 2000-11-17 2005-01-24 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
GEP20074148B (en) * 2002-04-23 2007-07-10 Bristol Myers Squibb Co Pyrrolo-triazine aniline compounds useful as kinase inhibitors
US7504521B2 (en) 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
PE20060421A1 (en) 2004-08-12 2006-06-01 Bristol Myers Squibb Co PROCEDURE FOR PREPARING A COMPOUND OF PYRROLOTRIAZINE ANILINE AS KINASE INHIBITORS
WO2013116948A1 (en) * 2012-02-09 2013-08-15 Perampalli Nekkar Praveen Rao Indolizine derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
CN1067054C (en) * 1994-04-01 2001-06-13 伊莱利利公司 1H-indole-3-glyoxylamide spla2 inhibitors
MX9700511A (en) * 1994-07-21 1997-04-30 Lilly Co Eli INDOLIZINE sPLA2 INHIBITORS.
WO1996040982A1 (en) * 1995-06-07 1996-12-19 Athena Neurosciences, Inc. Therapeutic inhibition of phospholipase a2 in neurodegenerative disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115210280A (en) * 2020-03-05 2022-10-18 波音公司 Schiff base oligomer

Also Published As

Publication number Publication date
EP1037630A2 (en) 2000-09-27
CA2308269A1 (en) 1999-05-20
WO1999024026A2 (en) 1999-05-20
WO1999024026A3 (en) 1999-07-15
JP2003522720A (en) 2003-07-29
WO1999024033A1 (en) 1999-05-20

Similar Documents

Publication Publication Date Title
AU1520699A (en) Methods for treatment of disorders of cardiac contractility
AU8769098A (en) System for treating patients with anxiety disorders
AU2301699A (en) System for the treatment of wafers
AU8676698A (en) Devices for providing therapeutic substances
GR3036315T3 (en) Indolinone compounds for the treatment of disease
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
AUPP609198A0 (en) Use of non-peptidyl compounds for the treatment of insulin related ailments
AU8569698A (en) Method of inducing apoptosis by reducing the level of thiamin
AU6910600A (en) Methods for the treatment of mental disorders
AU9763098A (en) Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU2508597A (en) Drug for the treatment of tumours
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
AU2325999A (en) Methods of neuroendocrine regulation of affective disorders
AU5038299A (en) Process for the biocidal treatment of surfaces
AU5042000A (en) Methods of treating proliferative disorders
ZA982454B (en) Method for treatment of chronic bronchitis using indole compounds.
AU7671198A (en) Methods for the inhibition of neuronal activity by local delivery of adenosi ne
AU2555397A (en) Macrophage stimulating protein for the treatment of gastrointestinal disorders
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU3460797A (en) Bicyclic compounds for controlling micturition
NO20012106L (en) Means for the treatment of disorders of bone metabolism
AU3596797A (en) Methods for the treatment of apolipoprotein e related diseases
AU2172899A (en) Aminosulphonylbenzamide derivatives as modulators of the activity of neuronal calcium channels
AU7080798A (en) Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase